<DOC>
	<DOCNO>NCT02333149</DOCNO>
	<brief_summary>This study multi-center , randomize , triple-blind , placebo-controlled parallel-group trial , participant offer N-of-1 trial . The purpose study assess efficacy safety melatonin ( 3 mg 6 mg ) compare placebo initial insomnia child attention-deficit disorder .</brief_summary>
	<brief_title>Melatonin Youth : N-of-1 Trials Stimulant-treated Attention Deficit Hyperactivity Disorder ( ADHD ) Population</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Schoolaged child adolescent age 6 17 year Confirmed diagnosis ADHD define Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Comorbid psychiatric/neurological diagnosis may affect sleep Comorbid seizure disorder Comorbid sleep disorder Concurrent use immunosuppressive drug , blood pressure drug , selective serotonin reuptake inhibitor anticoagulant drug ; Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Melatonin</keyword>
</DOC>